Skip to content

Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem.

Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem. This agreement is effective 1 March.

There are few brands in the prescription world with the equity and recognition of Tritace and Cardizem, which together account for annual sales in excess of $30 million. This takes Aspen Australia's annual turnover to over $130 million, and our company to another level. The addition of these two power brands to our stable of well-known, tried and trusted products is a coup, and will increase our prestige among health professionals.

The partnership with Sanofi-Aventis is another milestone for Aspen Pharmacare.

Content Last Reviewed On July 16, 2018

Scroll To Top